Strengths and limitations of commercial tests for hepatitis C virus RNA quantification

Chihiro Morishima; Minjun Chung; Ka Wing Ng; Donald J Brambilla; David R Gretch

doi:10.1128/JCM.42.1.421-425.2004

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification

J Clin Microbiol. 2004 Jan;42(1):421-5. doi: 10.1128/JCM.42.1.421-425.2004.

Authors

Chihiro Morishima¹, Minjun Chung, Ka Wing Ng, Donald J Brambilla, David R Gretch

Affiliation

¹ Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.

Abstract

The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantified specimens by 2.5- to 10.6-fold even at relatively low hepatitis C virus RNA concentrations. Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Hepacivirus / genetics*
Hepacivirus / isolation & purification
RNA, Viral / analysis*
Reagent Kits, Diagnostic*
Reproducibility of Results
Sensitivity and Specificity

Substances

RNA, Viral
Reagent Kits, Diagnostic

Abstract

Publication types

MeSH terms

Substances

Grants and funding